Table 3.
Results from anti–SARS-CoV-2 spike IgG seroconversion studies after complete (second dose) vaccination in patients with cancer.
| Study | n | Vaccine(s) administered | Days after the second dose (days, median) (IQR) | Serological response |
||
|---|---|---|---|---|---|---|
| Anti-S IgG antibody test platform | Seroconversion n (%) | Titre of anti-S IgG (UA/mL, median) (IQR) | ||||
| Addeo 2021 [16] | ||||||
| Mixed cancer | ||||||
| BNT162b2 cohort | 30 | BNT162b2 | 29 | Elecsysa | 28 (93) | 1232 (258–2500) |
| mRNA-1273 cohort | 93 | mRNA-1273 | 22 | 88 (95) | 2500 (442–2500) | |
| Haematological cancer | 22 | BNT162b2/mRNA-1273 | ·· | 17 (77) | 832 (24–2500) | |
| Solid cancer | 101 | ·· | 99 (98) | 2500 (514–2500) | ||
| Barrière 2021 [17] | ||||||
| Solid cancer | 42 | BNT162b2 | 15–27 | Elecsysa | 40 (95) | 245.2 (0–5467) |
| Healthy control | 24 | 24 (100) | 2517 (157.6–6318) | |||
| Fong 2021 [20] | ||||||
| Haematological cancer | 56 | BNT162b2 | 21 | Abbottb | 132 (86) | ·· |
| Solid cancer | 98 | |||||
| Goshen-Lago 2021 [21] | ||||||
| Solid cancer | 218 | BNT162b2 | 16 (2–54) | Liaisonc | 187 (86) | ·· |
| Herishanu 2021 [22] | ||||||
| CLL | 167 | BNT162b2 | 15 (14–17) | Elecsysa | 66 (40) | ·· |
| 52 | 27 (52) | 155 (7.6–490.3) | ||||
| Healthy control | 52 | 52 (100) | 1084 (128.9–1879) | |||
| Massarweh 2021 [26] | ||||||
| Solid cancer | 102 | BNT162b2 | 38 (32–43) | Abbottb | 92 (90) | 1931 (509–4386) |
| Healthy control | 78 | 40 (32–44) | 78 (100) | 7160 (3129–11,241) | ||
| Monin 2021 [27] | ||||||
| Haematological cancer | 5 | BNT162b2 | 37 (35–40) | In-house ELISAd | 3 (60) | ·· |
| Solid cancer | 19 | 37 (35–42) | 18 (95) | ·· | ||
| Healthy control | 12 | 40 (36–42) | 12 (100) | ·· | ||
| Pimpinelli 2021 [29] | ||||||
| MM | 42 | BNT162b2 | 14 | Liaisonc | 33 (79) | 106.7 (62.3–179.7)e |
| MPN | 50 | 44 (88) | 172.9 (106.5–257.0)e | |||
| Healthy control | 36 | 36 (100) | 353.3 (255.6–470.0)e | |||
| Roeker 2021 [31] | ||||||
| CLL | 44 | BNT162b2 | 21 (14–48) | Liaisonc | 23 (52) | ·· |
| Stampfer 2021 [32] | ||||||
| MM | 96 | BNT162b2/mRNA-1273 | 14–21 | In-house ELISAf | 64 (67) | 173.7 (SD = 1653.3) |
| Thakkar 2021 [33] | ||||||
| Mixed cancer | ||||||
| BNT162b2 cohort | 115 | BNT162b2 | 30 (19–53) | Abbottb | 110 (95) | 5173 (SD = 16,699) |
| mRNA-1273 cohort | 62 | mRNA-1273 | 58 (94) | 11,963 (SD = 18,742) | ||
| Haematological cancer | 66 | BNT162b2 (n = 115, 54%); mRNA-1273 (n = 62, 31%); single dose Ad26.COV2.S (n = 20, 10%); unknown mRNA-based (n = 3, 2%) | 28.5 | 56 (85) | 2528 (SD = 12,338) | |
| Solid cancer | 134 | 31.5 | 131 (98) | 7858 (SD = 18,103) | ||
| Tzarfati 2021 [34] | ||||||
| Haematological cancer | 315 | BNT162b2 | 32 (29–40) | Liaisonc | 235 (75) | 85 (11–172) |
| Matched | 69 | ·· | 52 (75) | 90 (12–185) | ||
| Healthy control | 108 | 33.5 (28–39) | 107 (99) | 157 (130–221) | ||
| Matched | 69 | ·· | 68 (99) | 173 (133–232) | ||
| Van Oekelen 2021 [35] | ||||||
| MM | ||||||
| BNT162b2 cohort | 177 | BNT162b2 | 51 (11–118) | COVID-SeroKlirg | 144 (81) | 149 (5–7882) |
| mRNA-1273 cohort | 76 | mRNA-1273 | 68 (89) | |||
| Healthy control | 67 | BNT162b2/mRNA-1273 | 67 (100) | 300 (21–3335) | ||
anti-S IgG, anti–SARS-CoV-2 spike protein S1/S2 immunoglobulin G; SD, standard deviation; ELISA, enzyme-linked immunosorbent assay; IQR, interquartile range; CLL, chronic lymphocytic leukaemia; MM, multiple myeloma; MPN, myeloproliferative neoplasms.
Elecsys Anti-SARS-CoV-2S assay, with a detection threshold of 0.80 U/mL for anti-S IgG.
LIAISON SARS-CoV-2 S1/S2 IgG test, with a detection threshold of 15 AU/mL for anti-S IgG.
Abbott SARS-CoV-2 IgG chemiluminescent microparticle immunoassay (CMIA), with a detection threshold of 50 UA/mL for anti-S IgG.
Evaluated via ELISA, with a detection threshold of OD 4-fold above background at 405 nM where EC50 was not reached at 1:25, and a value of 25 was assigned.
Geometric mean concentration.
Evaluated via ELISA, methods and detection threshold as described in Ref. [32].
COVID-SeroKlir, Kantaro SARS-CoV-2 IgG Ab kit, with a detection threshold of ≥5 AU/mL for anti-S IgG.